PL378573A1 - Kompozycje zawierające hemoglobinę płodową i endotoksynę bakteryjną oraz opcjonalnie, dodatkowe składniki wątroby płodowej - Google Patents

Kompozycje zawierające hemoglobinę płodową i endotoksynę bakteryjną oraz opcjonalnie, dodatkowe składniki wątroby płodowej

Info

Publication number
PL378573A1
PL378573A1 PL378573A PL37857304A PL378573A1 PL 378573 A1 PL378573 A1 PL 378573A1 PL 378573 A PL378573 A PL 378573A PL 37857304 A PL37857304 A PL 37857304A PL 378573 A1 PL378573 A1 PL 378573A1
Authority
PL
Poland
Prior art keywords
fetal
bacterial endotoxin
compositions
fetal hemoglobin
optionally additional
Prior art date
Application number
PL378573A
Other languages
English (en)
Other versions
PL211789B1 (pl
Inventor
Otto Westphal
Thierry Wälli
Reginald Gorczynski
Silke Müller
Jean-Pierre Mach
Alfred Hartmann
Wolfgang Bessler
Petra Hofmann
Ulrich Zähringer
Christian Alexander
Dem Esche Ulrich Vor
Artur J. Ulmer
Antonio Verdini
Original Assignee
Clinique La Prairie Research Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinique La Prairie Research Sa filed Critical Clinique La Prairie Research Sa
Publication of PL378573A1 publication Critical patent/PL378573A1/pl
Publication of PL211789B1 publication Critical patent/PL211789B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL378573A 2003-02-18 2004-02-18 Kompozycje zawierające hemoglobinę płodową i endotoksynę bakteryjną oraz opcjonalnie, dodatkowe składniki wątroby płodowej PL211789B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03003687A EP1449535B1 (en) 2003-02-18 2003-02-18 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components

Publications (2)

Publication Number Publication Date
PL378573A1 true PL378573A1 (pl) 2006-05-02
PL211789B1 PL211789B1 (pl) 2012-06-29

Family

ID=32731533

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378573A PL211789B1 (pl) 2003-02-18 2004-02-18 Kompozycje zawierające hemoglobinę płodową i endotoksynę bakteryjną oraz opcjonalnie, dodatkowe składniki wątroby płodowej

Country Status (20)

Country Link
US (1) US7968103B2 (pl)
EP (2) EP1449535B1 (pl)
JP (1) JP4619352B2 (pl)
KR (1) KR101102481B1 (pl)
CN (1) CN1750840A (pl)
AT (1) ATE324903T1 (pl)
AU (1) AU2004212703C1 (pl)
BR (1) BRPI0407311B8 (pl)
CA (1) CA2514485C (pl)
DE (1) DE60304989T2 (pl)
DK (1) DK1449535T3 (pl)
ES (1) ES2263859T3 (pl)
IL (1) IL169760A (pl)
IS (1) IS2294B (pl)
MX (1) MXPA05008797A (pl)
NO (1) NO334003B1 (pl)
NZ (1) NZ541417A (pl)
PL (1) PL211789B1 (pl)
RU (1) RU2366449C2 (pl)
WO (1) WO2004073728A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103427A2 (en) * 2006-03-06 2007-09-13 Wang Xiang H Medical use of bilirubin and its structural analogues
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2010006200A2 (en) * 2008-07-09 2010-01-14 Board Of Regents, The University Of Texas System Triggered release of drugs from polymer particles
WO2010123798A2 (en) 2009-04-20 2010-10-28 Galenbio, Inc. Compositions for transfection of biomolecules into cells
EP2789343A1 (en) * 2013-04-11 2014-10-15 Clinique La Prairie Novel hemoglobin-derived peptide based pharmaceutical compositions
EP3019186A4 (en) * 2013-07-12 2017-03-29 Patrick J. Casey Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473647A (en) * 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
EP0271521A4 (en) 1986-05-09 1989-11-14 Sloan Kettering Inst Cancer Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment.
ATE126698T1 (de) 1989-06-30 1995-09-15 American Cyanamid Co Verwendung eines phagozytise-aktievierenden stoffes : lps oder il-2 zur herstellung eines arzneimittels zur behandlung von staphylococcus- aureus-infektionen bei kühen.
EP0472467A3 (en) 1990-08-20 1993-03-17 Chiba Flour Milling Co. Ltd. Lps-containing analgesics and veterinary analgesics
JPH0499481A (ja) * 1990-08-20 1992-03-31 Chiba Seifun Kk 新規細菌、新規ｌｐｓ、新規免疫機能活性化剤、新規動物用免疫機能活性化剤
JPH0690745A (ja) * 1990-08-20 1994-04-05 Chiba Seifun Kk Ｌｐｓ産生菌、ｌｐｓ、ｌｐｓを含む医薬及び動物薬
JPH04187640A (ja) * 1990-11-22 1992-07-06 Chiba Seifun Kk 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤
DE539610T1 (de) * 1991-10-26 1993-12-16 Torf Ets Verfahren und Zusammensetzung zur Bestimmung der Immunologischen Aktivität von aktiven Substanzen enthaltende Lösungen.
JP3199081B2 (ja) * 1992-11-13 2001-08-13 味の素株式会社 抗腫瘍剤
DE4338812A1 (de) * 1993-11-15 1995-05-18 Braun Melsungen Ag Verwendung von Lösungen von vernetztem Hämoglobin zur Bekämpfung des septischen und hämorrhagischen Schocks bei Säugetieren
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US5580724A (en) * 1994-03-25 1996-12-03 Board Of Regents, The University Of Texas System Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis
US20020065211A1 (en) * 1995-03-23 2002-05-30 Biopure Corporation Increasing function of organs having reduced red blood cell flow
DK0863866T3 (da) 1995-10-06 2001-06-11 Vertex Pharma Butyrat-prodrugs afledt af mælkesyre
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
EP0856592A1 (en) 1997-02-04 1998-08-05 N.V. Bekaert S.A. A coating comprising layers of diamond like carbon and diamond like nanocomposite compositions
JP4256938B2 (ja) * 1997-02-04 2009-04-22 ナムローゼ・フェンノートシャップ・ベーカート・ソシエテ・アノニム ダイヤモンド状カーボン及びダイヤモンド状ナノコンポジット組成物の層を有するコーティング物
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
EP2292657A1 (en) * 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
EP2295968B1 (en) * 1999-12-03 2012-09-19 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
WO2002017965A1 (en) * 2000-08-28 2002-03-07 Akira Awaya Medicinal compositions
DE10103211C1 (de) * 2001-01-24 2002-07-18 Ursula Kastner Kulturmedium

Also Published As

Publication number Publication date
IS2294B (is) 2007-10-15
NZ541417A (en) 2008-08-29
BRPI0407311B8 (pt) 2021-11-30
KR20050111596A (ko) 2005-11-25
IS7940A (is) 2005-07-18
IL169760A (en) 2012-09-24
BRPI0407311A (pt) 2006-02-21
RU2005126141A (ru) 2006-01-27
KR101102481B1 (ko) 2012-01-05
WO2004073728A3 (en) 2004-10-07
WO2004073728A2 (en) 2004-09-02
EP1449535B1 (en) 2006-05-03
AU2004212703C1 (en) 2009-05-21
EP1449535A1 (en) 2004-08-25
US20080075742A1 (en) 2008-03-27
US7968103B2 (en) 2011-06-28
NO20054087L (no) 2005-11-08
NO20054087D0 (no) 2005-09-02
DE60304989D1 (de) 2006-06-08
AU2004212703B2 (en) 2008-10-30
BRPI0407311B1 (pt) 2020-12-29
AU2004212703A1 (en) 2004-09-02
NO334003B1 (no) 2013-11-11
DE60304989T2 (de) 2007-03-29
EP1601371A2 (en) 2005-12-07
RU2366449C2 (ru) 2009-09-10
CN1750840A (zh) 2006-03-22
CA2514485C (en) 2013-11-05
PL211789B1 (pl) 2012-06-29
JP2006518350A (ja) 2006-08-10
DK1449535T3 (da) 2006-09-11
JP4619352B2 (ja) 2011-01-26
ES2263859T3 (es) 2006-12-16
CA2514485A1 (en) 2004-09-02
MXPA05008797A (es) 2006-05-25
ATE324903T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
EP2567960A3 (en) Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis
AU6304394A (en) Urethanes and ureas that induce cytokine production
SG163517A1 (en) Antiviral compounds and methods
IL176298A (en) Imidazo [5,4 – c] pyridine compounds, preparations containing them and these compounds for use in the treatment and prevention of viral infection
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
EP2182006A3 (en) Compositions and methods for the treatment of immune related diseases
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
MY144318A (en) Methods of treating hiv infection.
MY138708A (en) Biaryloxymethylarenecarboxylic acids
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
AU2002303817A1 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2010052575A3 (en) Ngna compositions and methods of use
PL378573A1 (pl) Kompozycje zawierające hemoglobinę płodową i endotoksynę bakteryjną oraz opcjonalnie, dodatkowe składniki wątroby płodowej
WO2006034001A3 (en) Methods of treating hiv infection
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
AUPS234402A0 (en) Anti-tumour polycyclic carboxamides
PL1699468T3 (pl) Środek farmaceutyczny zawierający kompleks cynk-hialuronian do leczenia stwardnienia rozsianego
GB0123276D0 (en) Uses of agents that bind immune-system components
WO2005107871A3 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
WO2003014128A3 (de) Tumorhemmende cerverbindungen
WO2004053094A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU2002251847A1 (en) Vaccine and compositions for the prevention and treatment of neisserial infections
HU0401410D0 (en) Pharmaceutical compositions for the treatment of aids, sars or other virus infections and process for their preparation
HK1121496A (en) Novel pharmaceutical compositions for the treatment of virus infection and cancer